Posters have already discussed the remarks by our CEO during the recent Finance News Network. Reading the transcript, there appear to be two references to the Phase 1b trial. The first is a remark about 'really promising results' which could well refer to the scientific data being gathered from the trial around immunogenicity (anti-HER-2 antibody titres). The second remark includes a comment that 'they're doing great' which appears to reference the well being of the patients.
There will be many who are reading the tea leaves in regards to the efficacy of new generation vaccines. The article Cancer vaccines, long considered failures, are hot again by Emma Court suggests that Big Pharma are currently doing just that! The first movers who breakthrough in cancer vaccines will be as hot as the first movers in checkpoint inhibitors and Car-T.
IMU Price at posting:
2.0¢ Sentiment: Buy Disclosure: Held
